The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents
Basic Information
Publication number:
EP3807278
WO Application Number:
EP2019065686
Type:
European Patent Granted for NL
Status:
Patent in Force
Publication Title:
Title When Made Available For Viewing:
Reason Lapsed:
Application number:
EP19734289.2
WO Publication Number:
WO2019238929
EPO Publication Language:
English
SPC Number:
First Applicant Residence Country:
Sweden (SE)
Publications:
Dates
Filing date:
14/06/2019
Grant date:
31/08/2022
EP Publication Date:
21/04/2021
WO Publication Date:
19/12/2019
Claims Translations Received Date:
Claims Translation B1 Received Date:
21/11/2022
Claims Translation B2 Received Date:
Claims Translation B3 Received Date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Published:
Due To Cession Date:
Registration date:
31/08/2022
EP B1 Publication Date:
31/08/2022
EP B2 Publication Date:
EP B3 Publication Date:
Description Translation B1 Received Date:
Description Translation B2 Received Date:
Description Translation B3 Received Date:
Expiration date:
13/06/2039
Lapsed By Expiration Date:
Patent Validated Date:
06/12/2022
Revocation Date:
Invalidity Date:
Response To Novelty Search Report Received:
Patent Granting Request:
Lapsed date:
Applicant/holder
From:
31/08/2022
Name:
Astrazeneca AB
Address:
151 85 Södertälje, Sweden (SE)
From:
31/08/2022
Name:
CANCER RESEARCH TECHNOLOGY LIMITED
Address:
Angel Building
407 St. John Street, London EC1V 4AD, United Kingdom (GB)